Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T20:38:02.924Z.
Consensus retrieved: 2026-10-06T15:56:23.674Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T20:38:02.924Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 82e50dad054807a2d9cfcf78e4a189ad4456f1f756e397ab71e696e9b4df84c5
Forward PE Ratio (N/A) = Dated Quote Price ($6.75) / Consensus Forward EPS ($-3.00)
FORWARD PE RATIO
N/A
Cartesian Therapeutics, Inc.
Market Cap
$198.33M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | $198.33M | N/A |
| Exagen Inc. (XGN)vs › | $197.87M | N/A |
| Surrozen, Inc. (SRZN)vs › | $197.18M | N/A |
| Alector, Inc. (ALEC)vs › | $200.96M | N/A |
| RxSight, Inc. (RXST)vs › | $192.49M | N/A |
| Whitehawk Therapeutics Inc (WHWK)vs › | $205.80M | N/A |
| Zentalis Pharmaceuticals, Inc. (ZNTL)vs › | $190.07M | N/A |
| Pro-Dex, Inc. (PDEX)vs › | $207.27M | 21.01 |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $189.11M | N/A |
| Electra Therapeutics Inc. (ETRA)vs › | $208.31M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $6.75, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-3.00 | $-3.16 – $-2.77 | 4 | n/m |
| 2027-12-31 | $-4.16 | $-4.57 – $-3.64 | 4 | n/m |
| 2028-12-31 | $-4.20 | $-5.11 – $-3.51 | 4 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
